Hyundai Bioscience

At a glance

Hyundai Bioscience filed 48 disclosures in the last 12 months, including 18 5% holder, 3 insider and 1 issuance. The most recent key filing was on Oct 13: An insider's holding fell by 172,562 sh (conversion/exercise).

Revenue for 2025 was ₩3.5B, down 76.6% on 2024. It made an operating loss of ₩18.2B. Debt was 18% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩845.1M and operating loss of ₩10.2B.

The 2025 annual report lists 67 employees with an average tenure of 4.4 years and average pay of ₩78.7M, #397 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩85M each on average. It paid no cash dividend for 2025. (주)씨앤팜 and related parties held 10.24% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 11.79% on Oct 13.

From the 2025 annual report

Staff: 67 (40 men, 27 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.3B. Directors and auditors: 5, paid ₩426M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)씨앤팜 holds 10.04%; with 3 related parties the group holds 10.24% of common shares at year end (from 12.91% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports